# Why Your Gut Won't Heal: The Real Reason Chronic Gut Problems Keep Coming Back

> Diets, antimicrobials and probiotics can move the microbial picture without changing the host environment that produced it. A plain-language mechanistic reading of why the same dysbiosis pattern keeps rebuilding itself after treatment.

- **Author:** Mohammed Attallah (BiomeLogic)
- **Published:** 2026-03-27
- **Category:** Host Capacity Model
- **Tags:** dysbiosis, sibo, gut-healing, recurrence, colonocyte, butyrate, oxygen-gradient, barrier-integrity, host-capacity-model
- **Canonical URL:** https://biomelogic.net/articles/why-your-gut-wont-heal-chronic-recurrence
- **License:** CC BY-NC 4.0 — please cite "Mohammed Attallah, BiomeLogic" with link to https://biomelogic.net/articles/why-your-gut-wont-heal-chronic-recurrence.

---

You tried the diets, the supplements, the antibiotics, the probiotics, maybe even antimicrobial herbs. You felt better for a little while, then the bloating, constipation, diarrhea, brain fog, food reactions, inflammation, or discomfort came back again. A stool test may have shown dysbiosis (an unhealthy imbalance of gut bacteria), so the treatment focused on the bacteria. But the deeper question is this: why does your gut keep rebuilding the same environment that allows the problem to return?

That is the real issue. In many chronic gut cases, the main problem is not just “bad bacteria.” The deeper problem is that the host environment — meaning the oxygen level, the gut lining, the immune state, the fuel supply, and the energy production of the cells lining the colon — has shifted into a state that keeps favoring the wrong organisms. I call this way of thinking the Host Capacity Model.

Most gut approaches treat chronic gut problems like a bacteria problem: too many bad bacteria, not enough good bacteria, kill the bad ones, add the good ones, remove the foods that feed them. That idea is not completely wrong, but it misses the bigger layer. Bacteria live inside a controlled ecosystem. Your body controls that ecosystem through inflammation, mucus, bile acids, oxygen, immune signaling, and the metabolism of the cells lining the colon. If those host-controlled conditions are damaged, the wrong bacteria keep being selected over and over. In that sense, dysbiosis is often not the original cause. It is the result of a damaged environment.

The cells lining the colon are called colonocytes (colon lining cells). One of their most important jobs is to help keep the colon very low in oxygen. This matters because many beneficial bacteria, such as Faecalibacterium prausnitzii and Roseburia, are obligate anaerobes (they need very low oxygen to survive). Colonocytes normally use butyrate (a short-chain fatty acid made by gut bacteria from fiber) as their main fuel. When they burn butyrate well, they consume oxygen at the gut surface. This helps create what researchers describe as an oxygen sink (the process by which colon cells remove oxygen and preserve the low-oxygen environment of the gut). That low-oxygen environment protects beneficial anaerobes.

But when colonocytes stop burning butyrate properly, oxygen is not consumed the way it should be. More oxygen leaks into the gut lumen. Then beneficial anaerobic bacteria decline, while organisms like Klebsiella, E. coli, and other Proteobacteria gain an advantage because they can tolerate that disturbed environment better. So the issue is not only that “bad bacteria appeared.” The issue is that the gut environment changed in a way that helps them take over.

One of the main control switches involved here is PPAR-γ (peroxisome proliferator-activated receptor gamma, a cellular switch that helps colon cells burn butyrate, stay metabolically healthy, and resist inflammation). When PPAR-γ is working, colon cells keep butyrate oxidation going, maintain the oxygen sink, support the barrier, and keep inflammatory signaling lower. But in an inflamed gut, LPS (lipopolysaccharide, an inflammatory outer-membrane molecule from gram-negative bacteria) activates TLR4 (Toll-like receptor 4, an immune alarm receptor). TLR4 then activates NF-κB (a major inflammatory signaling pathway). NF-κB interferes with PPAR-γ and also helps increase inflammatory cytokines like TNF-α and IL-1β, which further suppress PPAR-γ. So the very pathway needed to restore healthy colonocyte metabolism gets blocked by ongoing inflammation.

That same suppression has another effect. When PPAR-γ drops, the gut is less able to keep iNOS (inducible nitric oxide synthase, an enzyme that makes nitric oxide during inflammation) under control. More iNOS means more nitric oxide, and that contributes to more nitrate in the gut. This matters because some harmful bacteria can use nitrate as an energy source.

This is one of the most important ideas in the whole model: in chronic gut inflammation, certain bacteria are not mainly feeding on your food. They are feeding on your inflammation. During inflammation, the host creates nitrate. Bacteria like Klebsiella and E. coli can use that nitrate through nitrate respiration (a way of making more energy by using nitrate instead of oxygen). This gives them far more usable energy than simple fermentation gives beneficial bacteria. That extra energy changes everything, because the bacteria can now afford expensive survival systems.

This is where the idea of bacterial fitness cost becomes important. A fitness cost means that every bacterial defense system costs energy to run. If bacteria have a large energy supply, they can run many defenses at once. If their energy supply is restricted, those defenses become harder to maintain. In other words, the goal is not always just to kill the bacteria directly. Sometimes the more powerful strategy is to remove the ecological fuel that allows them to afford all of their defenses.

What are those defenses?

One of the biggest is the efflux pump system, especially AcrAB-TolC. This is basically a molecular pump that throws harmful compounds out of the bacterial cell. The genes acrA, acrB, and tolC build this system. Regulatory proteins like MarA, SoxS, and RamA help turn it on under stress. This pump can eject various antibiotics and also plant antimicrobials like thymol, carvacrol, and cinnamaldehyde — the active compounds in oregano, thyme, and cinnamon. That means these bacteria are not always sitting there passively getting hit. They may be actively pumping compounds back out.

Another defense is siderophore production. Siderophores are iron-grabbing molecules that bacteria release when the host tries to hide iron from them. The body uses a defense called nutritional immunity to reduce free iron, but bacteria fight back. Enterobactin is built by genes in the entABCDEF cluster. Salmochelin is built from the iroBCDE genes. Yersiniabactin involves genes like irp1, irp2, and fyuA. Aerobactin is another iron acquisition system often carried on mobile DNA. All of these systems cost energy, but they help bacteria steal iron and keep growing even in an inflamed, iron-restricted environment.

Another major defense is the capsule, a thick protective outer layer around bacteria like Klebsiella. This capsule is built using genes in the cps locus. The capsule helps block immune attack, resist antimicrobial peptides, and reduce how easily immune cells can engulf the bacteria. It acts like armor. But armor costs energy to build and maintain.

Then there are the heat shock proteins, which help bacteria survive stress. Proteins like DnaK, GroEL/GroES, Lon, and ClpB help refold damaged proteins, remove badly damaged ones, and keep the bacterial machinery functioning under inflammation, oxidative stress, fever, or treatment pressure. These systems are also costly, but nitrate-derived energy helps the bacteria afford them.

Another huge issue is biofilm formation. A biofilm is a protective bacterial community enclosed in a sticky matrix. Instead of floating freely, bacteria attach to surfaces and build a shield around themselves. A signaling molecule called c-di-GMP helps regulate the shift into biofilm behavior. Inside a biofilm, some bacteria on the outer layers stay active, but deeper bacteria can become dormant and very hard to eliminate.

That leads to persister cells and dormancy systems, which are a major reason relapse happens. Bacteria can use toxin-antitoxin systems to shift into a low-metabolism survival state. Important systems here include MazEF, RelBE, and HipAB. In simple terms, these systems help shut down protein production and growth when the bacteria are stressed. That makes the bacteria temporarily inactive. Antibiotics often target growing bacteria, dividing bacteria, or bacteria making proteins. Dormant persister cells are doing much less of that, so they survive treatment. When treatment stops and the environment is still favorable, they wake back up and rebuild the population. That is why relapse can be predictable rather than mysterious.

Bacteria also communicate with each other through quorum sensing. One important system involves LuxS and AI-2 (a shared bacterial communication signal). When enough bacteria are present, this signaling helps coordinate behaviors like biofilm formation, adhesion, capsule production, and virulence. The problem is that some beneficial bacteria also use similar communication signals, so blindly blocking quorum sensing may not be as simple as it sounds.

This is why I keep coming back to the idea of fitness cost. The more bacterial defense systems they have to run at once — efflux pumps, siderophores, capsule, stress proteins, biofilm maintenance, dormancy transitions — the more energy they need. If the inflamed gut keeps supplying nitrate and oxygen shifts, the bacteria can afford those defenses. If you restore host metabolism and remove the ecological advantage, then suddenly those same defenses become more expensive for the bacteria to maintain. The goal is to make the environment hostile enough that their survival programs become too costly.

This also explains why low FODMAP often helps symptoms but does not produce durable healing. Low FODMAP lowers fermentable carbohydrates, so it can reduce gas, bloating, water shifts, and discomfort. But if the major pathobionts are being fueled by host-derived nitrate, then low FODMAP does not remove that deeper fuel source. It may reduce symptoms, but it does not necessarily correct the ecological problem.

At the center of this whole host failure is NAD⁺ (nicotinamide adenine dinucleotide, a core molecule needed for mitochondrial energy production and cellular regulation). Colonocytes need NAD⁺ both to oxidize butyrate and to run sirtuins, which are proteins that help control inflammation, mitochondrial repair, and energy metabolism. Two of the most important are SIRT1 and SIRT3. SIRT1 helps activate PGC-1α (PPARGC1A, a master regulator of mitochondrial biogenesis and repair) and also helps restrain NF-κB signaling. SIRT3 works inside mitochondria and helps maintain the electron transport chain, fatty acid oxidation, and antioxidant defenses like SOD2.

When NAD⁺ falls, SIRT1 and SIRT3 lose function. Then mitochondrial repair weakens, oxidative stress increases, and butyrate oxidation drops even more. Why does NAD⁺ fall? Because inflammation drives up CD38 (an enzyme that destroys NAD⁺), increases PARP activity (a DNA repair system that consumes NAD⁺ during oxidative and inflammatory damage), and can suppress NAMPT (a key enzyme in the NAD⁺ salvage pathway that helps rebuild NAD⁺). That creates a vicious loop: more LPS, more TLR4, more NF-κB, more CD38, more NAD⁺ depletion, weaker sirtuin function, worse mitochondrial health, worse butyrate oxidation, more oxygen leak, more dysbiosis, then more LPS again.

- - 

Another important protective system is intestinal alkaline phosphatase, or IAP. IAP helps detoxify LPS in the gut lumen by removing phosphate groups from it, which makes LPS less inflammatory. Butyrate helps support IAP expression. So when butyrate metabolism is working, the gut is not only maintaining low oxygen, it is also helping neutralize one of its main inflammatory triggers. When butyrate oxidation fails, IAP can fall too, so the gut loses another defense.

Then there is trained immunity, which helps explain why inflammation can stay high even after bacteria go down somewhat. Trained immunity means innate immune cells, such as monocytes and macrophages, become epigenetically reprogrammed after repeated exposure to things like LPS. Important chromatin marks discussed in the literature include H3K4me3 and H3K27ac, which keep inflammatory genes more ready to fire. In simple terms, the immune system learns to overreact. So even if bacterial levels improve, the immune system may still respond as if the threat is high, making relapse and persistent inflammation more likely.

This same inflammatory environment can also affect the brain. Chronic gut inflammation can increase IDO (indoleamine 2,3-dioxygenase, an enzyme that diverts tryptophan away from beneficial pathways and into the kynurenine pathway). That shift can increase compounds like quinolinic acid, which stimulates NMDA receptors and may contribute to brain fog, anxiety, overstimulation, poor stress tolerance, and cognitive dysfunction. At the same time, less tryptophan may be available for beneficial microbial indole production and AhR signaling, which normally help support the barrier and immune tolerance.

Genetics also matters. Variants in TLR4 can affect how strongly someone reacts to LPS. Variants in SIRT1, PPARGC1A, or CD38 may affect mitochondrial resilience or NAD⁺ vulnerability. Variants affecting sulfur handling, such as CBS and SUOX, may influence how much hydrogen sulfide stress the mitochondria face. Hydrogen sulfide can inhibit Complex IV of the electron transport chain. Variants in MUC2 may affect mucus integrity. No single SNP determines everything, but multiple weak points in the same system can add up.

This framework also helps explain why common treatments fail. Antimicrobial herbs may suppress some organisms, but they may also trigger stress responses, be pumped out through efflux pumps, or increase LPS exposure when gram-negative bacteria are damaged. Berberine has useful actions, but it also influences mitochondrial pathways, including AMPK and aspects of Complex I signaling, and that may not always be ideal in someone whose colonocyte bioenergetics are already very fragile. Probiotics may help transiently, but if the ecology remains high in oxygen, high in inflammation, low in butyrate oxidation, and rich in nitrate, many introduced organisms will not colonize durably. PPAR-γ support may make sense mechanistically, but if NF-κB is still dominating, the pathway remains blocked.

The deeper question is not just, “How do I kill the bad bacteria?” The deeper question is, how do I restore the host environment so the gut stops selecting for them? That means paying attention to colonocyte metabolism, butyrate oxidation, PPAR-γ, oxygen control, nitrate generation, NAD⁺ status, SIRT1, SIRT3, IAP, barrier function, mucus integrity, bile stress, mitochondrial damage, and immune reprogramming — not just the microbes.

This is not a finished model, and it is not a final clinical protocol. But it is a mechanistic framework built from primary research to explain why chronic gut dysfunction becomes so stable, why relapse is so common, why treatment failure is often predictable, and why the answer may require going upstream into host bioenergetics and ecological control instead of staying focused only on bacterial killing.

The people who fail every standard gut protocol deserve a better explanation than, “the bacteria came back.” Sometimes they came back because the gut environment never stopped inviting them.

References

- Litvak Y, Byndloss MX, Bäumler AJ. Colonocyte metabolism shapes the gut microbiota. Science. 2018;362(6418):eaat9076.

- Byndloss MX, et al. Microbiota-activated PPAR-γ signaling inhibits dysbiotic Enterobacteriaceae expansion. Science. 2017;357(6351):570–575.

- Park B, et al. Crosstalk between butyrate oxidation in colonocyte and butyrate-producing bacteria. iScience. 2024;27(9):110853.

- Winter SE, et al. Host-derived nitrate boosts growth of E. coli in the inflamed gut. Science. 2013;339(6120):708–711.

- Winter SE, Bäumler AJ. Dysbiosis in the inflamed intestine: Chance favors the prepared microbe. Gut Microbes. 2014;5(1):71–73.

- Gonçalves P, et al. Butyrate and the fine-tuning of colonic homeostasis. International Journal of Molecular Sciences. 2021;22(6):3061.

- Camacho-Pereira J, et al. CD38 dictates age-related NAD decline and mitochondrial dysfunction through an SIRT3-dependent mechanism. Cell Metabolism. 2016;23(6):1127–1139.

- Chini CCS, et al. CD38 ecto-enzyme in immune cells is induced during aging and regulates NAD⁺ and NMN levels. Nature Metabolism. 2020;2(11):1284–1304.

- Swamynathan MM, et al. Epithelial NAD⁺ depletion drives mitochondrial dysfunction and contributes to intestinal inflammation. Frontiers in Immunology. 2023.

- Bai P, et al. PARP-1 inhibition increases mitochondrial metabolism through SIRT1 activation. Cell Metabolism. 2011;13(4):461–468.

- Yeung F, et al. Modulation of NF-κB-dependent transcription and cell survival by the SIRT1 deacetylase. EMBO Journal. 2004;23(12):2369–2380.

- Hirschey MD, et al. SIRT3 regulates mitochondrial fatty-acid oxidation by reversible enzyme deacetylation. Nature. 2010;464(7285):121–125.

- Malo MS, et al. Intestinal alkaline phosphatase is a gut mucosal defense factor maintained by enteral nutrition. PNAS. 2008;105(10):3551–3556.

- Lallès JP. Intestinal alkaline phosphatase: a review of its enzyme role in the intestinal barrier function. Microorganisms. 2022;10(4):746.

- Netea MG, et al. Trained immunity: a program of innate immune memory in health and disease. Science. 2016;352(6284):aaf1098.

- Donohoe DR, et al. The Warburg effect dictates the mechanism of butyrate-mediated histone acetylation and cell proliferation. Cell Metabolism. 2012;16(4):466–477.

- Zong W, et al. Disruption of intestinal oxygen balance in acute colitis alters the gut microbiome. Gut Microbes. 2024;16(1):2361493.

- Lewis K. Persister cells. Annual Review of Microbiology. 2010;64:357–372.

- Gerdes K, Maisonneuve E. Bacterial persistence and toxin-antitoxin loci. Annual Review of Microbiology. 2012;66:103–123.

- Flemming HC, Wingender J. The biofilm matrix. Nature Reviews Microbiology. 2010;8(9):623–633.

- Nikaido H. Multidrug resistance in bacteria. Annual Review of Biochemistry. 2009;78:119–146.

- Hengge R. Principles of c-di-GMP signalling in bacteria. Nature Reviews Microbiology. 2009;7(4):263–273.

---

*Source of record: https://biomelogic.net/articles/why-your-gut-wont-heal-chronic-recurrence. This plain-text endpoint is provided for AI retrieval and citation systems (ChatGPT, Perplexity, Claude, Gemini, Bing Copilot).*